Nurix Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nurix Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q4 2024.
  • Nurix Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending November 30, 2024 was -$58.5M, a 39.5% decline year-over-year.
  • Nurix Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending November 30, 2024 was -$194M, a 34.5% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$194M, a 34.5% decline from 2023.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$144M, a 20.2% increase from 2022.
  • Nurix Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$180M, a 53.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$194M -$58.5M -$16.6M -39.5% Sep 1, 2024 Nov 30, 2024 10-K 2025-01-28
Q3 2024 -$177M -$49M -$12M -32.4% Jun 1, 2024 Aug 31, 2024 10-Q 2024-10-11
Q2 2024 -$165M -$44.5M -$20.3M -83.5% Mar 1, 2024 May 31, 2024 10-Q 2024-10-11
Q1 2024 -$145M -$41.5M -$785K -1.93% Dec 1, 2023 Feb 29, 2024 10-Q 2024-10-11
Q4 2023 -$144M -$42M +$4.76M +10.2% Sep 1, 2023 Nov 30, 2023 10-K 2025-01-28
Q3 2023 -$149M -$37M +$8.73M +19.1% Jun 1, 2023 Aug 31, 2023 10-Q 2024-10-11
Q2 2023 -$157M -$24.3M +$21.1M +46.5% Mar 1, 2023 May 31, 2023 10-Q 2024-10-11
Q1 2023 -$179M -$40.7M +$1.8M +4.23% Dec 1, 2022 Feb 28, 2023 10-Q 2024-10-11
Q4 2022 -$180M -$46.7M -$9.02M -23.9% Sep 1, 2022 Nov 30, 2022 10-K 2025-01-28
Q3 2022 -$171M -$45.7M -$16.9M -58.5% Jun 1, 2022 Aug 31, 2022 10-Q 2023-10-12
Q2 2022 -$154M -$45.4M -$19M -72.1% Mar 1, 2022 May 31, 2022 10-Q 2023-10-12
Q1 2022 -$135M -$42.5M -$18.3M -75.2% Dec 1, 2021 Feb 28, 2022 10-Q 2023-10-12
Q4 2021 -$117M -$37.7M -$17.8M -89.3% Sep 1, 2021 Nov 30, 2021 10-K 2023-02-09
Q3 2021 -$99.4M -$28.8M -$10.3M -55.7% Jun 1, 2021 Aug 31, 2021 10-Q 2022-10-06
Q2 2021 -$89.1M -$26.4M -$34M -448% Mar 1, 2021 May 31, 2021 10-Q 2022-10-06
Q1 2021 -$55.1M -$24.3M -$11.9M -95.9% Dec 1, 2020 Feb 28, 2021 10-Q 2022-10-06
Q4 2020 -$43.2M -$19.9M -$6.4M -47.3% Sep 1, 2020 Nov 30, 2020 10-K 2021-02-16
Q3 2020 -$36.8M -$18.5M -$16.1M -663% Jun 1, 2020 Aug 31, 2020 10-Q 2021-10-14
Q2 2020 -$20.8M $7.58M +$10.6M Mar 1, 2020 May 31, 2020 10-Q 2021-10-14
Q1 2020 -$31.4M -$12.4M -$9.71M -361% Dec 1, 2019 Feb 29, 2020 10-Q 2021-10-14
Q4 2019 -$21.7M -$13.5M Sep 1, 2019 Nov 30, 2019 10-K 2021-02-16
Q3 2019 -$2.43M Jun 1, 2019 Aug 31, 2019 10-K 2021-02-16
Q2 2019 -$3.07M Mar 1, 2019 May 31, 2019 10-K 2021-02-16
Q1 2019 -$2.69M Dec 1, 2018 Feb 28, 2019 10-K 2021-02-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.